Scagliotti Giorgio V

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. pmc Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing
    Luisella Righi
    Divisions of Pathology, University of Torino, Regione Gonzole 10, Torino, Orbassano 10043, Italy
    BMC Cancer 13:114. 2013
  2. doi request reprint The emerging role of MET/HGF inhibitors in oncology
    Giorgio V Scagliotti
    Department of Oncology, University of Turin, San Luigi Hospital, Italy
    Cancer Treat Rev 39:793-801. 2013
  3. doi request reprint Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study
    Giorgio Vittorio Scagliotti
    Department of Clinical and Biological Sciences, University of Turino, Orbassano, Italy
    J Thorac Oncol 7:1823-9. 2012
  4. doi request reprint Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Turin, San Luigi Hospital, Orbassano Turin, Italy
    Clin Lung Cancer 13:391-5. 2012
  5. doi request reprint Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
    Ann Oncol 23:2082-7. 2012
  6. doi request reprint Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Orbassano Torino, Italy
    J Thorac Oncol 7:1053-7. 2012
  7. doi request reprint Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
    Giorgio V Scagliotti
    University of Turin, Orbassano Turin, Italy
    J Clin Oncol 30:2070-8. 2012
  8. doi request reprint The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, S Luigi Hospital, Orbassano, Italy
    Cancer Treat Rev 38:292-302. 2012
  9. pmc Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation
    Marco Lo Iacono
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    J Transl Med 9:100. 2011
  10. pmc Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer
    Silvia Saviozzi
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    BMC Cancer 6:200. 2006

Detail Information

Publications53

  1. pmc Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing
    Luisella Righi
    Divisions of Pathology, University of Torino, Regione Gonzole 10, Torino, Orbassano 10043, Italy
    BMC Cancer 13:114. 2013
    ....
  2. doi request reprint The emerging role of MET/HGF inhibitors in oncology
    Giorgio V Scagliotti
    Department of Oncology, University of Turin, San Luigi Hospital, Italy
    Cancer Treat Rev 39:793-801. 2013
    ..Evidence is emerging for identification of aberrant MET activity biomarkers and selection of patient subpopulations that may benefit from targeted MET and HGF inhibitor treatment...
  3. doi request reprint Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study
    Giorgio Vittorio Scagliotti
    Department of Clinical and Biological Sciences, University of Turino, Orbassano, Italy
    J Thorac Oncol 7:1823-9. 2012
    ....
  4. doi request reprint Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Turin, San Luigi Hospital, Orbassano Turin, Italy
    Clin Lung Cancer 13:391-5. 2012
    ..All patients will be tested for biomarkers, and the results will provide a wealth of information on the role of tivantinib in treating nonsquamous NSCLC...
  5. doi request reprint Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
    Ann Oncol 23:2082-7. 2012
    ..Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences. Preventing or delaying bone metastases may improve outcomes...
  6. doi request reprint Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Orbassano Torino, Italy
    J Thorac Oncol 7:1053-7. 2012
    ..Tasisulam sodium (hereafter referred to as tasisulam) is a novel anticancer compound that induces apoptosis and exhibits antiangiogenesis activity in a broad range of cancer models, including non-small-cell lung cancer (NSCLC)...
  7. doi request reprint Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
    Giorgio V Scagliotti
    University of Turin, Orbassano Turin, Italy
    J Clin Oncol 30:2070-8. 2012
    ..This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC...
  8. doi request reprint The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, S Luigi Hospital, Orbassano, Italy
    Cancer Treat Rev 38:292-302. 2012
    ..This review outlines the role of IGF-1R signaling in solid tumors with a particular focus on NSCLC, and provides an overview of clinical data...
  9. pmc Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation
    Marco Lo Iacono
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    J Transl Med 9:100. 2011
    ..The purpose of the present study was to investigate the expression of AURKA in non small cell lung cancer (NSCLC) specimens and to correlate its mRNA or protein expression with patients' clinico-pathological features...
  10. pmc Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer
    Silvia Saviozzi
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    BMC Cancer 6:200. 2006
    ..Aim of this study was to identify and validate RGs for use in the differentiation of normal and tumor lung expression profiles...
  11. pmc Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Giorgio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Orbassano Turin, Italy 10043
    Oncologist 15:436-46. 2010
    ....
  12. ncbi request reprint Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Ann Oncol 18:x32-41. 2007
    ....
  13. ncbi request reprint The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences Thoracic Oncology Unit S Luigi Hospital, Italie
    Rev Mal Respir 23:16S137-16S147. 2006
    ..This review focuses on the actual scenario of targeted therapies in NSCLC...
  14. ncbi request reprint Emerging drugs for mesothelioma
    Giorgio Vittorio Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, Orbassano Torino, Italy
    Expert Opin Emerg Drugs 12:127-37. 2007
    ..This review summarizes standard chemotherapy options and focuses on the molecular basis of the newest biologically targeted therapies to be implemented in the near future, in the management of MPM...
  15. ncbi request reprint Optimizing chemotherapy for patients with advanced non-small cell lung cancer
    Giorgio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole 10, Orbassano, Turin, Italy
    J Thorac Oncol 2:S86-91. 2007
    ..Overall, the wealth of data with docetaxel in advanced NSCLC suggests that it plays an important role in first-line treatment and, as a single agent, can be considered a reasonable approach in elderly and frail patients...
  16. doi request reprint Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole, 10, Orbassano Torino, Italy
    J Clin Oncol 26:3543-51. 2008
    ..Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting...
  17. doi request reprint The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies
    Giorgio Scagliotti
    Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano Torino, Italy
    Oncologist 14:253-63. 2009
    ..Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials...
  18. doi request reprint Updated clinical information on multitargeted antifolates in lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Clin Lung Cancer 10:S35-40. 2009
    ..These hypothesis-generating findings are currently validated in prospective studies...
  19. doi request reprint New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin Thoracic Oncology Unit, San Luigi Hospital, Orbassano, Torino, Italy
    Clin Lung Cancer 9:S122-8. 2008
    ..Consequently, the differential expression of TS according to histology might explain the different activity of pemetrexed according to histology, as recently postulated...
  20. doi request reprint Nonsmall cell lung cancer in never smokers
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Regione Gonzole, 10, Orbassano, Turin 10043, Italy
    Curr Opin Oncol 21:99-104. 2009
    ..To summarize the available knowledge about nonsmall cell lung cancer (NSCLC) in never smokers in terms of biological and clinical-pathological findings...
  21. doi request reprint A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S Luigi Hospital, Regione Gonzole 10, Orbassano Torino 10043, Italy
    Lung Cancer 68:420-6. 2010
    ..The primary end point was assessment of response rate...
  22. doi request reprint Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole 10, 10043 Torino, Italy
    J Clin Oncol 30:172-8. 2012
    ....
  23. ncbi request reprint Antimetabolites and cancer: emerging data with a focus on antifolates
    Giorgio V Scagliotti
    Professor of Respiratory Medicine, University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Regione Gonzole, 10, 10043 Orbassano TO, Italy
    Expert Opin Ther Pat 16:189-200. 2006
    ..This review will describe the most recent findings and their potential clinical applications...
  24. doi request reprint The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, S Luigi Hospital, Orbassano, Italy
    J Thorac Oncol 4:1568-71. 2009
    ..Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens...
  25. ncbi request reprint Current status of adjuvant chemotherapy in NSCLC
    G V Scagliotti
    Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, University of Turin, Torino, Italy
    Ann Oncol 17:v62-3. 2006
  26. ncbi request reprint Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Gonzaga Thoracic Oncology Unit, Orbassano Torino, Italy
    Oncology (Williston Park) 18:32-7. 2004
    ..This article briefly summarizes the current evidence that supports the role of pemetrexed-based combinations in clinical trials for chemonaive patients with advanced NSCLC...
  27. ncbi request reprint Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, S Luigi Hospital, Regione Gonzole 10, 10043 Orbassino, Turin, Italy
    Semin Oncol 32:S5-8. 2005
    ....
  28. ncbi request reprint Current development of adjuvant treatment of non-small-cell lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Thoracic Oncology Unit, Orbassano Torino, Italy
    Clin Lung Cancer 6:S63-70. 2004
    ..Genomic- and proteomic-driven chemotherapy as well as molecularly targeted therapies may represent additional areas of near-future clinical investigations...
  29. ncbi request reprint Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Orbassano, Torino, Italy
    J Natl Cancer Inst 95:1453-61. 2003
    ..However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established...
  30. ncbi request reprint The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer
    Giorgio V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Regione Gonsole 10, 10043 Turin, Italy
    Clin Cancer Res 11:5011s-5016s. 2005
    ..In this article, we will discuss the findings of the Adjuvant Lung Cancer Project Italy study in the context of the International Adjuvant Lung Cancer and British Big Lung Trial...
  31. ncbi request reprint Adjuvant therapy in completely resected non-small-cell lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Thoracic Oncology Unit, Regione Gonzole, 10, 10043 Orbassano Torino, Italy
    Curr Oncol Rep 5:318-25. 2003
    ..It is hoped that a specific meta-analysis will be performed on the basis of these data...
  32. ncbi request reprint Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer
    Giorgio V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital Thoracic Oncology Unit, Orbassano Torino, Italy
    Lung Cancer 46:S13-21. 2004
    ..Phase-III research is currently underway to confirm the favorable phase-II results with docetaxel...
  33. ncbi request reprint A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
    Giorgio V Scagliotti
    University of Tovino, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole 10, Orbassano Torino 10043, Italy
    Lung Cancer 50:91-6. 2005
    ..BAC is relatively resistant to commonly used chemotherapy regimens. A phase II study with single agent paclitaxel in patients with stages IIIB, IV or recurrent BAC was performed...
  34. ncbi request reprint Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Nat Clin Pract Oncol 2:190-1. 2005
  35. ncbi request reprint Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, S Luigi Hospital, Italy
    Lung Cancer 50:S18-9. 2005
    ..With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC...
  36. ncbi request reprint Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, S Luigi Gonzaga Hospital, Italy
    Oncology (Williston Park) 14:15-9. 2000
    ....
  37. ncbi request reprint Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Turin
    J Clin Oncol 20:4285-91. 2002
    ..To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC)...
  38. ncbi request reprint ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    P Ceppi
    Thoracic Oncology Unit, Orbassano, Torino, Italy
    Ann Oncol 17:1818-25. 2006
    ....
  39. ncbi request reprint Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
    ....
  40. pmc Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
    Br J Cancer 101:1543-8. 2009
    ..Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC)...
  41. ncbi request reprint Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005
    ..Based on resource consumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the treatment of advanced NSCLC in Italy...
  42. ncbi request reprint Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
    ....
  43. pmc Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences and Department of Radiotherapy, University of Torino, S Luigi Hospital, Regione Gonzole 10, Orbassano, Turin 10043, Italy
    Br J Cancer 94:1375-82. 2006
    ..Docetaxel-cisplatin induction therapy followed by concurrent docetaxel and thoracic radiotherapy is a feasible treatment option, showing good clinical activity and tolerability, for locally advanced NSCLC...
  44. ncbi request reprint Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Lung Cancer 34:261-9. 2001
    ..CONCLUSION: In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated...
  45. ncbi request reprint Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
    G Selvaggi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Ann Oncol 15:28-32. 2004
    ..We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival...
  46. ncbi request reprint Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
    ..In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood...
  47. ncbi request reprint Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
    S Novello
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
    Ann Oncol 16:1662-6. 2005
    ....
  48. ncbi request reprint State of the art in mesothelioma
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Orbassano Torino, Italy
    Ann Oncol 16:ii240-5. 2005
  49. ncbi request reprint Role of erythropoietin in the treatment of lung cancer associated anaemia
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Azienda Ospedaliera S Luigi, 10043 Orbassano, Torino, Italy
    Lung Cancer 34:S91-4. 2001
    ..This 'functional' level would be in keeping with the body's physiological erythropoietin response...
  50. ncbi request reprint Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    S Bovio
    Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
    J Endocrinol Invest 29:298-302. 2006
    ..Notwithstanding that our subjects were at increased risk of lung cancer, the rate of adrenal metastases was low. We think that the present results can be generalized even if we may disclose the lack of histological diagnosis...
  51. ncbi request reprint Tyrosine kinase signal transduction inhibitors. Clinical trials
    Giorgio Vittorio Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Orbassano, Torino, Italy
    Suppl Tumori 1:S34-6. 2002
  52. ncbi request reprint Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Turin, Italy
    Lung Cancer 38:S13-9. 2002
    ....
  53. ncbi request reprint [Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience]
    Elena Gelormino
    Epidemiologia dei tumori, ASO S Giovanni Battista e CPO Piemonte, Torino
    Epidemiol Prev 31:25-33. 2007
    ..To develop a method for adapting the best available cancer practice guidelines (CPGs) to the regional oncology network in Piedmont (NW of Italy, with about 4.3 million residents)...